Article
Serum islet cell autoantibodies during interferon alpha treatment in patients with HCV-genotype 4 chronic hepatitis.
Clinical & developmental immunology - 1 Mar 2006
Badra Gamal, Waked Imam, Selmi Carlo, Saleh Saleh M, El-Shaarawy Ahmed, Lotfy Mahmoud
Abstract excerpt
Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4 (HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-a (IFNa) treatment for HCV may trigger serum autoantibodies against pancreatic islet cells (ICA) in a subgroup of patients. Available data on the incidence of ICA during IFNa therapy for chronic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.